Innovative financing mechanism accelerates global roll out of vaccine against world’s leading cause of child deaths
Innovative financing mechanism accelerates global roll out of vaccine against world’s leading cause of child deaths
Pneumococcal vaccines are complex vaccines that would normally reach low-income countries 10-15 years after their introduction in industrialised countries.
Thanks to the pneumococcal Advance Market Commitment, children in 60 Gavi-eligible countries are being immunised against the main cause of pneumonia today.
The 2019 Pneumococcal AMC Annual Report gives an overview of the activities linked to the implementation of the pilot Advance Market Commitment from 1 January to 31 December 2019.
It was developed by the AMC Secretariat at Gavi, in collaboration with the World Bank and UNICEF’s Supply Division.
View previous Annual Reports:
2018 | 2017 | 2016 | 2015 | 2014-2015 | 2013-2014 | 2012-2013 | 2011-2012 | 2010-2011 | 2009-2010
If you represent a vaccine manufacturer and are interested in participating in the pneumococcal AMC, this section explains how to make your offer.
Suppliers must sign a registration agreement relating to the AMC terms and conditions.
UNICEF issues Calls for Supply Offers following the publication of the Strategic Demand Forecast.
